Drugs / Q-Griffithsin
Q-Griffithsin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05437029 | Jun → Oct 2022 | — | Kenneth Palmer | Unknown | No outcome recorded |
| Phase 1 | NCT05122260 | Nov 2021 → Jan 2022 | — | Kenneth Palmer | Completed | No outcome recorded |
| Phase 1 | NCT04032717 | Jul 2019 → Feb 2021 | — | Rhonda Brand | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05180500 Comparator | Mar → Dec 2022 | COVID-19 | Sharon Hillier | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q-Griffithsin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04032717 ↗ |
| Known as | GRFT | “Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study...” NCT04032717 ↗ |
| Known as | Q-GRFT | “Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study...” NCT04032717 ↗2“Q-Griffithsin (Q-GRFT) nasal spray is an investigational product that has broad spectrum antiviral activity.” NCT05122260 ↗ “intranasal Q-Griffithsin (Q-GRFT) drug product designed for COVID-19 prophylaxis.” PMID 37699630 ↗ Sep 2023 |
| Action | Inhibit | “GRFT inhibited entry of pseudo-particles typed with ANDV envelope glycoprotein into host cells” PMID 33251157 ↗ Nov 2020 |
| Modality | Protein / enzyme biologic | “modified plant protein called Q-Griffithsin” NCT04032717 ↗ |
| Route | Intranasal | “intranasal spray administered as a single dose” NCT05122260 ↗ |